Drug Trial Radar · NCT00283335
The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol
Last checked: Nov 20, 2026Latest source record: Oct 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,531
Actual
Start
Jun 1991
Primary completion
Sep 1998
Study completion Aug 1999
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Parke-Davis; Fournier Labs
- First posted
- Jan 27, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, up to 73 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a double-blind randomized trial comparing 1200 mg per day of gemfibrozil with placebo in 2531 men with coronary heart disease, an HDL-C of 40mg/dl or less, an LDL-C of 140 mg/dl or less, and triglycerides of 300mg/dl or less. The primary outcome was nonfatal myocardial infarction(MI) or death from coronary causes. The median follow-up was 5.1 years. There was a risk reduction of 22% in the primary outcome (p=.0006) and 24% risk reduction in the combined endpoint of stroke, MI, and CHD death. The rate of events was reduced by raising HDL-C and lowering triglycerides without lowering LDL-C (N Engl J Med 1999;341:410-418).
Conditions
- Coronary Heart Disease
Interventions
gemfibrozilDrug
PlaceboOther
Matching placebo tablets taken once per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- incidence of nonfatal myocardial infarction or death from coronary heart diseaseTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.